ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CTXR Citius Pharmaceuticals Inc

0.71
0.003 (0.42%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Citius Pharmaceuticals Inc NASDAQ:CTXR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.003 0.42% 0.71 0.64 1.00 0.73 0.6881 0.73 671,810 05:00:05

Citius Pharmaceuticals to Present at the 5th Annual Dawson James Small Cap Growth Conference

24/10/2019 1:00pm

PR Newswire (US)


Citius Pharmaceuticals (NASDAQ:CTXR)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Citius Pharmaceuticals Charts.

CRANFORD, N.J., Oct. 24, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on developing adjunctive cancer care and critical care drug products, announced today that the Company will present at the 5th Annual Dawson James Small Cap Growth Conference on Tuesday, Oct 29, 2019 at 4:30-4:50 PM ET in Track 2 - Preserve Ballroom B. The conference is being held at the Wyndham Grand Hotel in Jupiter, Florida on October 28-29, 2019.  

Mr. Leonard Mazur, Chairman of Citius Pharmaceuticals will be delivering an overview of the company including recent highlights as well as answering questions from investors. Citius Pharmaceuticals, Inc. will also be available for one-on-one meetings. To arrange a meeting with the Company, please contact Mr. Andrew Scott: ascott@citiuspharma.com.

About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs; by using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.

Contact:

Andrew Scott                                                              
Vice President, Corporate Development                                                       
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com 

Cision View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-5th-annual-dawson-james-small-cap-growth-conference-300944622.html

SOURCE Citius Pharmaceuticals, Inc.

Copyright 2019 PR Newswire

1 Year Citius Pharmaceuticals Chart

1 Year Citius Pharmaceuticals Chart

1 Month Citius Pharmaceuticals Chart

1 Month Citius Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock